Mindbloom

Mindbloom: At-Home Ketamine Therapy for Mental Health

Mindbloom is a U.S. provider of at-home ketamine therapy that combines ketamine administration with clinical and psychological support. The company presents itself as the only at-home ketamine therapy provider with proven results for depression, anxiety, and post-traumatic stress disorder (PTSD). Its approach is based on neuroplasticity, the mechanism by which the brain can modify its neural connections, and it maintains that ketamine helps rewire neural pathways to promote recovery.

Programs and Treatment Areas

The company structures its offerings into programs targeting various conditions and goals. Focus areas include anxiety, depression, burnout, emotional regulation, feeling stuck, grief, habit change, PTSD, resilience, relationships, and self-love. It also offers educational resources such as articles on ketamine-assisted therapy (KAT), psychedelic integration, and preparation for psychedelic experiences.

Treatment Modalities

Mindbloom offers two ketamine formats: subcutaneous injectables and sublingual tablets. According to the company, 81% of clients prefer injectables. The company describes itself as the number one at-home provider offering both options. Treatment with sublingual tablets is carried out with ketamine compounded by pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA).

Clinical Process and Safety

Mindbloom pairs individuals with licensed clinicians trained to diagnose and treat anxiety, depression, and other mental health conditions. If the clinician determines that ketamine is an appropriate treatment, they may prescribe ketamine tablets. The company provides important safety information, including possible side effects such as sedation, dissociation, psychiatric events, dependence, anxiety, increases in blood pressure or heart rate, respiratory depression, urinary symptoms, altered time perception, dry mouth, elevated intraocular or intracranial pressure, loss of appetite, confusion, nausea/vomiting, blurred vision, and slurred speech. It also warns about contraindications and offers treatment guidelines, such as not driving after the session until you have slept a full night, avoiding benzodiazepines or stimulants 24 hours before, not consuming alcohol, fasting from solid foods 3 hours before and liquids 1 hour before, and having a treatment monitor present.

Research and Results

The company supports its approach with clinical studies. A peer-reviewed study on its client outcomes was published in the Journal of Affective Disorders in 2022, titled "At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial." Additionally, the three largest peer-reviewed clinical studies on psychedelic therapy followed over 11,000 Mindbloom clients. The company states that it has facilitated 200,000 ketamine therapy sessions.

Coverage and Financing

Mindbloom notes that clients may be eligible to reimburse over 50% of the program cost through insurance, or use HSA/FSA dollars. The company offers an online tool to check eligibility.